Premium
Centessa Pharmaceuticals PLC (CNTA)
NASDAQ
Hot Features
Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of cen... Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.04 | -0.10060362173 | 39.76 | 39.83 | 39.58 | 1442012 | 39.70626281 | DR |
| 4 | 0.12 | 0.30303030303 | 39.6 | 39.975 | 39.56 | 1168188 | 39.75861412 | DR |
| 12 | 11.42 | 40.3533568905 | 28.3 | 40.26 | 25.17 | 2685131 | 38.80269255 | DR |
| 26 | 12.63 | 46.6223698782 | 27.09 | 40.26 | 21.5 | 1963662 | 33.79277376 | DR |
| 52 | 27.31 | 220.064464142 | 12.41 | 40.26 | 11.77 | 1658327 | 28.59853478 | DR |
| 156 | 34.89 | 722.360248447 | 4.83 | 40.26 | 4.5 | 859277 | 23.12211733 | DR |
| 260 | 17.69 | 80.2995914662 | 22.03 | 40.26 | 2.885 | 587736 | 21.33214 | DR |
Transactions différées
Pour obtenir des transactions en temps réel, améliorez votre compte
Passer à la version en temps réel| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
